Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Single Dose, 3x3 Partial Replicated Crossover Study to Evaluate the Pharmacokinetics and Safety/Tolerability Between BR1010 and Co-administration of BR1010-1 and BR1010-2 in Healthy Volunteers

Trial Profile

A Randomized, Open-label, Single Dose, 3x3 Partial Replicated Crossover Study to Evaluate the Pharmacokinetics and Safety/Tolerability Between BR1010 and Co-administration of BR1010-1 and BR1010-2 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Amlodipine/fimasartan/hydrochlorothiazide (Primary) ; Amlodipine/fimasartan; Hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Pharmacokinetics
  • Sponsors Boryung Pharmaceutical
  • Most Recent Events

    • 08 Jan 2019 Status changed from not yet recruiting to completed.
    • 23 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top